BR0315082A - Preparação sólida - Google Patents

Preparação sólida

Info

Publication number
BR0315082A
BR0315082A BR0315082-8A BR0315082A BR0315082A BR 0315082 A BR0315082 A BR 0315082A BR 0315082 A BR0315082 A BR 0315082A BR 0315082 A BR0315082 A BR 0315082A
Authority
BR
Brazil
Prior art keywords
solid preparation
preparation
active ingredient
insulin
except
Prior art date
Application number
BR0315082-8A
Other languages
English (en)
Inventor
Masahiko Koike
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32064024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0315082(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BR0315082A publication Critical patent/BR0315082A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARAçãO SóLIDA". A presente invenção fornece uma preparação sólida contendo um sensibilizador insulínico e um ingrediente ativo (exceto sensibilizadores insulínicos), que é útil como um medicamento terapêutico para o diabete etc., e que é superior nas características de preparação, tais como a uniformidade de conteúdo e a propriedade de dissolução do sensibilizador insulínico e do ingrediente ativo (exceto sensibilizadores insulínicos), da dureza de preparação e outras.
BR0315082-8A 2002-10-07 2003-10-06 Preparação sólida BR0315082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002294045 2002-10-07
PCT/JP2003/012781 WO2004030700A1 (ja) 2002-10-07 2003-10-06 固形製剤

Publications (1)

Publication Number Publication Date
BR0315082A true BR0315082A (pt) 2005-08-16

Family

ID=32064024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315082-8A BR0315082A (pt) 2002-10-07 2003-10-06 Preparação sólida

Country Status (26)

Country Link
US (1) US9101660B2 (pt)
EP (1) EP1561472B2 (pt)
JP (2) JP4236553B2 (pt)
KR (2) KR100820609B1 (pt)
CN (1) CN100427143C (pt)
AU (1) AU2003271103B2 (pt)
BR (1) BR0315082A (pt)
CA (1) CA2501587C (pt)
CO (1) CO5700740A2 (pt)
CR (1) CR7797A (pt)
CY (1) CY1114863T1 (pt)
DK (1) DK1561472T3 (pt)
ES (1) ES2437072T5 (pt)
HK (1) HK1080385A1 (pt)
IL (1) IL167835A (pt)
MA (1) MA27487A1 (pt)
MX (1) MXPA05003668A (pt)
NO (1) NO332993B1 (pt)
NZ (2) NZ552559A (pt)
PL (1) PL219608B1 (pt)
PT (1) PT1561472E (pt)
RU (1) RU2357757C2 (pt)
SI (1) SI1561472T1 (pt)
UA (1) UA80991C2 (pt)
WO (1) WO2004030700A1 (pt)
ZA (1) ZA200503507B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
WO2006118137A1 (ja) * 2005-04-26 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. ビグアナイド系薬物を含有する粒状製剤
MY149306A (en) * 2005-12-22 2013-08-30 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
KR101220643B1 (ko) * 2006-08-16 2013-01-14 알리코제약(주) 사포그릴레이트 함유 경구투여 형태의 약제
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP4832271B2 (ja) * 2006-12-11 2011-12-07 花王株式会社 粉末圧縮錠剤
NZ583346A (en) 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
WO2009030257A1 (en) * 2007-09-05 2009-03-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
CN101417130B (zh) * 2007-10-22 2010-10-06 鲁南制药集团股份有限公司 一种治疗ⅱ型糖尿病及其并发症的药物组合物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2010084504A2 (en) * 2008-05-26 2010-07-29 Sun Pharmaceutical Industries Ltd. A stable, oral solid dosage form
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2465896C2 (ru) * 2011-01-20 2012-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция пролонгированного действия
CN105125539A (zh) * 2015-08-05 2015-12-09 浙江华海药业股份有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
BR9710265A (pt) † 1996-07-12 1999-08-10 Daiichi Seiyaku Co Materiais moldados á compressão rapidamente desintegráveis e processo para produção dos mesmos
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
KR20060105005A (ko) 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
JPH1160476A (ja) 1997-08-25 1999-03-02 Taisho Pharmaceut Co Ltd 圧縮固形組成物
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
MY154010A (en) † 1998-07-28 2015-04-30 Takeda Pharmaceutical Rapidly disintegrable solid preparation
US6117451A (en) † 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
DE69939485D1 (de) † 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
MXPA01006511A (es) 1998-12-24 2004-03-19 Metabasis Therapeutics Inc Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes.
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001035940A2 (en) 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
MY125516A (en) † 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
FR2812547B1 (fr) 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2002087965A (ja) * 2000-09-14 2002-03-27 Lion Corp 口中崩壊性アスピリン含有錠剤
CA2424770A1 (en) 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1552832A1 (en) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation

Also Published As

Publication number Publication date
KR20070119095A (ko) 2007-12-18
NZ539711A (en) 2007-09-28
MA27487A1 (fr) 2005-08-01
MXPA05003668A (es) 2005-06-08
CR7797A (es) 2005-11-15
ES2437072T3 (es) 2014-01-08
PL219608B1 (pl) 2015-06-30
JP4236553B2 (ja) 2009-03-11
KR100820609B1 (ko) 2008-04-10
NO332993B1 (no) 2013-02-11
CA2501587C (en) 2008-06-03
RU2357757C2 (ru) 2009-06-10
US20050287207A1 (en) 2005-12-29
CN1717253A (zh) 2006-01-04
EP1561472B2 (en) 2021-01-20
US9101660B2 (en) 2015-08-11
ES2437072T5 (es) 2021-10-13
JP2004149521A (ja) 2004-05-27
PT1561472E (pt) 2013-12-09
ZA200503507B (en) 2006-08-30
AU2003271103B2 (en) 2008-02-28
NZ552559A (en) 2008-04-30
CN100427143C (zh) 2008-10-22
AU2003271103A1 (en) 2004-04-23
SI1561472T1 (sl) 2014-01-31
CY1114863T1 (el) 2016-12-14
NO20052239D0 (no) 2005-05-06
KR20050070039A (ko) 2005-07-05
PL376176A1 (en) 2005-12-27
JP2008208141A (ja) 2008-09-11
HK1080385A1 (en) 2006-04-28
EP1561472A1 (en) 2005-08-10
EP1561472B1 (en) 2013-10-02
CA2501587A1 (en) 2004-04-15
WO2004030700A1 (ja) 2004-04-15
CO5700740A2 (es) 2006-11-30
NO20052239L (no) 2005-06-29
IL167835A (en) 2010-11-30
DK1561472T3 (da) 2013-11-11
RU2005113999A (ru) 2005-12-10
UA80991C2 (en) 2007-11-26
EP1561472A4 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
BR0315082A (pt) Preparação sólida
BR0015048A (pt) Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação
GT200100183A (es) Derivados de quinolina y quinazolina.
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
GT200200188A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BRPI0418029B8 (pt) formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40
BR0207631A (pt) Atuadores de inalador dosador pressurizado (pmdi) e produtos de formulação em solução de aerossol medicinal compreendendo estes atuadores
BRPI0407001A (pt) Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica
SE0001899D0 (sv) New compounds
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ECSP077368A (es) Mecanismo de visualización de dosis para un dispositivo para la administración de fármacos
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
ATE227986T1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
Mohd Effendy et al. The effects of tualang honey on bone metabolism of postmenopausal women
BR0009914A (pt) Medicamento, e, usos de um inibidor, e de um ativador de quinase h-sgk humana regulada por volume celular
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
BRPI0409924A (pt) ácidos amino carboxìlicos substituìdos
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]